Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flupiwell P
- Development stage
- Unknown
- Lead developer
- Primus Remedies
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Flupiwell P** is a fixed-dose combination oral tablet developed by Primus Remedies, containing 100 mg of flupirtine and 325 mg of paracetamol (acetaminophen). It is indicated for the management of acute and chronic pain, particularly pain associated with musculoskeletal spasms, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tension headaches, dysmenorrhea, and post-operative recovery. Flupirtine is a centrally acting, non-opioid analgesic that functions as a selective neuronal potassium channel opener (SNEPCO), stabilizing the resting membrane potential of neurons and indirectly antagonizing NMDA receptors to suppress pain transmission. Paracetamol acts as an analgesic and antipyretic, primarily by inhibiting cyclooxygenase (COX) enzymes in the central nervous system, thereby reducing prostaglandin synthesis. Together, the two active ingredients provide synergistic pain relief and muscle relaxation.
- Brand names
- Flupiwell P
- Other names
- flupirtine + acetaminophenflupirtine + paracetamolflupirtine and acetaminophenflupirtine and paracetamolflupirtine maleate + acetaminophenflupirtine maleate + paracetamolflupirtine maleate and acetaminophenflupirtine maleate and paracetamolflupirtine maleate/acetaminophenflupirtine maleate/paracetamolflupirtine/acetaminophenflupirtine/paracetamol
02
Targets
GABRR (GABA-A receptor subunit rho)KCNQ2 (Potassium voltage-gated channel subfamily KQT member 2)KCNQ3 (Potassium voltage-gated channel subfamily Q member 3)KCNQ5 (Potassium voltage-gated channel subfamily KQT member 5)NMDAR (Glutamate receptor ionotropic, NMDA)KACh (G protein–activated inwardly rectifying potassium channel)GABAA (Gamma-aminobutyric acid receptor)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on Flupiwell P.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flupiwell P.